The PDUFA date of February 23, 2027 is the next key catalyst. Approval would expand ZORYVE's label to infants aged 3-24 months, addressing an unmet need. Monitor FDA review and any advisory committee meeting.
Drug in focus
ARQT drug pipeline →ZORYVE
▲ Bullish Named in this press release- Impact
- Phase
- Approved (commercial stage)
- Time to market
- Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
- Next catalyst
- PDUFA date · Feb 23, 2027 98d
What to watchThe next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $28.26entry
- T+1 · 17h ago −3.93%α −2.02% · $27.15
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Arcutis presented caregiver-reported outcomes from the INTEGUMENT-INFANT trial of ZORYVE cream 0.05% in infants aged 3-24 months with mild to moderate atopic dermatitis at the ACAAI meeting. The data showed improvements in itch, symptoms, and quality of life with a favorable safety profile. The sNDA for this infant indication is under FDA review with a PDUFA date of February 23, 2027.
Key Facts
- INTEGUMENT-INFANT trial enrolled 101 infants aged 3-24 months with mild to moderate atopic dermatitis.
- No serious adverse events or severe treatment-emergent adverse events reported; at least 97.9% had no application-site irritation.
- 46.6% of infants achieved ≥25% improvement in itch at 10 minutes after first application, increasing to 66.7% at 4 hours.
- Mean POEM scores decreased from 14.5 at baseline to 6.5 at Week 4, shifting from moderate to mild disease severity.
- sNDA for ZORYVE cream 0.05% in infants aged 3-24 months is under FDA review with PDUFA target action date of February 23, 2027.
- ZORYVE cream 0.05% is already approved in the US for children aged 2-5 years with mild to moderate atopic dermatitis.
Financial Impact
Expanding the approved age range to infants could increase the addressable patient population; 60% of children develop atopic dermatitis symptoms within their first year. No revenue estimates provided.
Risk Factors
- FDA may issue a Complete Response Letter or request additional data.
- Competition from other topical treatments for pediatric atopic dermatitis.
- The ATM program filed 9 days ago adds potential dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402608 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Viewing Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers